Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085696 · ClinicalTrials.gov registry record · Phase 2
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
A Phase 2 study of Follicular Lymphoma and B-cell Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 13
- Study locations
NCT00085696: Completed Phase 2 study of Follicular Lymphoma and B-cell Lymphoma, sponsored by Millennium Pharmaceuticals.
NCT00085696 is a Phase 2 study of Follicular Lymphoma and B-cell Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 66 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (51% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085696, a Phase 2 study of Follicular Lymphoma and B-cell Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.
Conditions Studied
Interventions
- DRUG VELCADE and rituximab
Study Locations (13)
Georgia
- Emory University Cancer Institute, Winship Cancer Institute - Atlanta
- Georgia Cancer Specialists - Marietta
Illinois
- Rush University Medical Center - Chicago
- Midwest Cancer Research Group - Skokie
California
- UCLA School of Medicine - Los Angeles
Florida
- Florida Cancer Specialists - Fort Myers
Kansas
- Cancer Center of Kansas - Wichita
Missouri
- Oncology/Henmatology Associates of Kansas City - Kansas City
Ohio
- Mid Ohio Oncology/Hematology Inc. - Columbus
South Carolina
- Charleston Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00085696 record still lists
NCT00085696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which VELCADE and rituximab is the first listed.
NCT00085696 lists 13 locations in 11 states (Georgia, Illinois, California).
Frequently Asked Questions
What is clinical trial NCT00085696 about?
NCT00085696 is a clinical study titled "VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma". The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to...
What is the current status of trial NCT00085696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2004-05.
What conditions does trial NCT00085696 study?
This clinical trial studies the following conditions: Follicular Lymphoma, B-cell Lymphoma, Marginal Lymphoma.
What interventions are being tested in trial NCT00085696?
The interventions under investigation include: VELCADE and rituximab (DRUG).
Who is sponsoring clinical trial NCT00085696?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085696 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00085696's enrollment target sits among peer trials
66 39th of 89 higher than 51 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia